Avandia should come with warning on heart disease, FDA told

GlaxoSmithKline's diabetes drug Avandia should stay on the market with a strong warning about increased risks of heart diseases, an expert panel recommended to the Food and Drug Administration on Monday. The scientists on the panel said they were frustrated by the data presented at a day-long meeting. The committee of scientists voted 20-3 to conclude that Avandia does increase risks of heart disease in type 2 diabetes, but the committee declined to recommend that the drug be pulled from the market. The experts urged the FDA to study the effects of the drug and of a substitute drug, Actos, marketed by Takeda Pharmaceuticals.

Source:www.marketwatch.com